European medicines agency accepts marketing authorization application for enfortumab vedotin

Tokyo & bothell, wash.--(business wire)--astellas pharma inc. (tse: 4503, president and ceo: kenji yasukawa, ph.d., “astellas”) and seagen inc. (nasdaq:sgen) today announced that a marketing authorization application (maa) for enfortumab vedotin was accepted by the european medicines agency (ema). the maa requests review of enfortumab vedotin for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received a programmed death receptor-1 (pd-1) or progra
SGEN Ratings Summary
SGEN Quant Ranking